Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reimbursement In Brief

This article was originally published in The Gray Sheet

Executive Summary

HHS Office of Inspector General says Illinois should reduce Medicaid rates for diabetes test strips, and that Medicare is paying so-called G modifier claims inappropriately in reports last week. More reimbursement news.

You may also be interested in...



Reimbursement Briefs: AMA Wants ICD-10 Halt; News From CMS, AHRQ And OIG

AMA asks CMS to reconsider ICD-10 implementation. CMS explores specialist payment models. AHRQ quality measures clearinghouse endorses new Medicare hip and knee replacement measures tied to readmissions and complications. More reimbursement news.

Molecular Dx Labs’ Concerns Shift To Coverage Issues With Release Of Interim Medicare Payment Amounts

Now that CMS has posted the interim payment amounts for more than 100 new molecular pathology codes, industry is concerned whether the tests will be covered at all.

Molecular Dx Labs Fret Over Medicare Payment Setting, Or, In Some Cases, Lack Thereof

The industry’s angst is growing several months after CMS announced a plan to task contractors with independently setting regional payments for more than 100 new molecular diagnostic codes. A breakdown in the process so far, stakeholders say, could have a lasting impact on small, venture-backed labs.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032042

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel